AmacaThera begins human trials for AMT-143, a non-opioid local anesthetic for post-operative pain relief.
AmacaThera Inc, a clinical-stage biotech company, begins human trials for AMT-143, a non-opioid, slow-release local anesthetic for post-operative pain relief. AMT-143 uses the AmacaGel platform to provide sustained pain relief, making it the first therapeutic product formulated to be delivered via this technology. The trial will evaluate safety, tolerability, pharmacokinetics, and clinical activity.
May 15, 2024
3 Articles